Clinical trials: Non-small Cell Lung Cancer(NSCLC)
Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 as a monotherapy or in…
- Conditions
- Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT06747585
- Testing
- ALE.P02, Pembrolizumab
- Where
- 41 sites in United States, France and 6 more
- Volunteers
- 235 people
- Sponsor
- Alentis Therapeutics AG
Non Small Cell Lung Cancer Metastatic
A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain
The researchers are doing this study is to find out whether treating brain metastasis with SRS after 3 months of therapy with osimertinib is better than treating with osimertinib alone in people with NSCLC.
- Trial name
- NCT06741085
- Testing
- osimertinib, stereotactic radiosurgery (SRS)
- Where
- 8 sites in United States
- Volunteers
- 56 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Cancer, Non-Small Cell Lung Cancer
Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
The purpose of this trial is: - To characterize the safety profile of motesanib when used in combination with carboplatin/paclitaxel (CP), with panitumumab or with CP and panitumumab in patients with advanced non-small cell lung…
- Trial name
- NCT00094835
- Testing
- Panitumumab, Motesanib diphosphate, Paclitaxel
- Volunteers
- 51 people
- Sponsor
- Amgen
Cancer, Solid Tumor
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.
- Conditions
- Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
- Trial name
- NCT05500508
- Testing
- AMXT1501, DFMO
- Where
- 7 sites in United States, Australia
- Volunteers
- 15 people
- Sponsor
- Aminex Therapeutics, Inc.
Non-small Cell Lung Cancer
Australian Retrospective Analysis of EGFRm Advanced & Metastatic NSCLC Patients Treated With 1L or 2L Osimertinib.
This is a retrospective, observational study of treatment patterns and clinical outcomes in Australian EGFRm advanced and metastatic non-small cell lung cancer patients treated with first-line osimertinib or second-line…
- Trial name
- NCT07213076
- Where
- Australia
- Volunteers
- 350 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer, Metastatic Lung Cancer
Vapor Ablation for Localized Cancer Lesions of the Lung (VAPORIZE)
This study is a prospective, single-arm, multi-center, pilot trial of Bronchoscopic Thermal Vapor Ablation for Lung Cancer (BTVA-C) in patients with primary lung cancer or metastatic cancer in the lung.
- Conditions
- Non Small Cell Lung Cancer, Metastatic Lung Cancer, Lung Cancer
- Trial name
- VAPORIZE (NCT03198468)
- Testing
- Bronchoscopic Thermal Vapor Ablation
- Where
- Australia
- Volunteers
- 8 people
- Sponsor
- Uptake Medical Technology, Inc.
NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs
The goal of this prospective study is to explore the safety and preliminary efficacy of stereotactic body radiotherapy (SBRT) combined with ORIENT-31 regimen (Sintilimab plus bevacizumab plus platinum-doublet chemotherapy) for…
- Trial name
- NCT06775743
- Testing
- ORIENT-31 regimen, SBRT
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Fudan University
Carcinoma, Non-Small-Cell Lung
Sorafenib in Resected Non-small Cell Lung Carcinoma
This is an open-label, single-armed, multicentric, phase II study of Sorafenib treatment following surgery for NSCLC. The primary hypothesis is to increase the progression-free survival (PFS) of the experimental group in…
- Trial name
- SIRN (NCT00532025)
- Testing
- Sorafenib
- Where
- 6 sites in Germany
- Volunteers
- 134 people
- Sponsor
- Johannes Gutenberg University Mainz
Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung)
TailorDose Lung: Decentralized TDM of Taxanes and ALK Inhibitors Using Capillary Self-Sampling
This study will evaluate whether people with non-small cell lung cancer (NSCLC) can collect small blood samples themselves using a finger-prick sampling kit.
- Trial name
- TD-Lung (NCT07823725)
- Testing
- True Dose® Capillary Self-Sampling System
- Where
- 2 sites in Sweden
- Volunteers
- 40 people
- Sponsor
- Karolinska Institutet
Non-small Cell Lung Cancer
PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery
This is a pharmacodynamic study to evaluate the effect of gefitinib as induction therapy for patients who have resectable, Epidermal growth factor receptor (EGFR) sensitizing mutation lung cancer.
- Trial name
- PROGRESS (NCT02804776)
- Testing
- Gefitinib
- Where
- Singapore
- Volunteers
- 15 people
- Sponsor
- National Cancer Centre, Singapore
Breast Cancer, Breast Neoplasms, Endometrial Cancer, Endometrial Neoplasm
GEN1047 for Solid Tumors - First in Human (FIH) Trial
The purpose of this trial is to measure the following in participants with solid tumors who receive GEN1047: The side effects seen with GEN1047 What the body does with GEN1047 once it is administered What GEN1047 does to the body…
- Conditions
- Breast Cancer, Breast Neoplasms, Endometrial Cancer, Endometrial Neoplasm, Ovarian Cancer, Ovarian Neoplasms, Squamous Non Small Cell Lung Cancer (NSCLC-SCC)
- Trial name
- NCT05180474
- Testing
- GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells.
- Where
- 36 sites in United States, Belgium and 7 more
- Volunteers
- 179 people
- Sponsor
- Genmab
Lung Cancer
Gemcitabine and Docetaxel in Treating Patients With Inoperable Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Trial name
- NCT00075517
- Testing
- docetaxel, gemcitabine hydrochloride
- Where
- 12 sites in France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Adenocarcinoma of the Lung, Non-small Cell Lung Cancer
Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
Hsp90 inhibitor AUY922 and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT01259089
- Testing
- erlotinib hydrochloride, Hsp90 inhibitor AUY922, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Northwestern University
Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC)
A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
This is a Phase 1, open-label, multicenter study of continuous oral dosing of AZD4635 administered to patients with advanced solid malignancies.
- Conditions
- Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC), Colorectal Carcinoma (CRC)
- Trial name
- NCT02740985
- Testing
- AZD4635, Durvalumab, Abiraterone Acetate
- Where
- 17 sites in United States
- Volunteers
- 313 people
- Sponsor
- AstraZeneca
Carcinoma, Non Small Cell Lung (NSCLC)
Locally Advanced NSCLC Hyperfractionated RT
This is a prospective phase II study designed to evaluate an accelerated and adaptive RT approach for locally-advanced non-small cell lung cancer (NSCLC).
- Trial name
- ADAPT (NCT03128008)
- Testing
- Carboplatin, Paclitaxel, Daily hyperfractionated radiation therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Duke University
Non-Small Cell Lung Cancer
A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
A Phase 1/2 multi-center open-label study of BGB324 (bemcentinib) as a single agent (Run-in Cohort) and in combination with erlotinib (Arms A, B, and C) in participants with Stage IIIb or Stage IV non-small cell lung cancer…
- Trial name
- NCT02424617
- Testing
- Erlotinib, Bemcentinib
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- BerGenBio ASA
Non-small Cell Lung Cancer
Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI
This is a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to evaluate the efficacy and safety of Toripalimab injection (JS001) or placebo combined with chemotherapy in Advanced Non-small Cell Lung…
- Trial name
- NCT03924050
- Testing
- TORIPALIMAB INJECTION(JS001 )
- Where
- 2 sites in China
- Volunteers
- 440 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Renal Cancer, Non Small Cell Lung Cancer (NSCLC)
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers
The purpose of this study is to determine if a new investigational drug called Panobinostat is safe, tolerable and to obtain an initial assessment of efficacy, when given in combination with Sorafenib for the treatment of certain…
- Conditions
- Renal Cancer, Non Small Cell Lung Cancer (NSCLC), Soft Tissue Sarcoma
- Trial name
- NCT01005797
- Testing
- Panobinostat (LBH589), Sorafenib
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Medical University of South Carolina
Non-Small Cell Lung Cancer
Repositioning Immunotherapy in VetArans With Lung Cancer
This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC.
- Trial name
- RIVAL (NCT06275360)
- Testing
- Nivolumab
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- VA Office of Research and Development
Non-small Cell Lung Cancer
Real World Observational Study of Pembrolizumab for Chinese Advanced NSCLC
This observational study is designed to assess the efficacy and safety of pembrolizumab for the treatment of Chinese advanced NSCLC.
- Trial name
- NCT04153097
- Where
- 8 sites in China
- Volunteers
- 500 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.